Palisade Bio
PALI
7 hedge funds and large institutions have $463K invested in Palisade Bio in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
30% less funds holding
Funds holding: 10 → 7 (-3)
52% less capital invested
Capital invested by funds: $956K → $463K (-$494K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$572K |
| 2 |
AC
Armistice Capital
New York
|
-$185K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$17K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$5K |
PALI Hedge Fund Activity: Q1 2019 in Review
7 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2019, worth a combined $463K — down 52% from $956K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PALI and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, cutting an estimated $572K.
- 7 institutional investors held Palisade Bio (PALI) as of Q1 2019, down from 10 in Q4 2018.
- Funds reported $463K of Palisade Bio stock for Q1 2019, down 52% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q1 2019 and 3 closed out, a net change of -3 holders.
- The largest Palisade Bio seller in Q1 2019 was Sabby Management, an estimated $572K sold.
Based on aggregated 13F filings for Q1 2019.